AZD599, another MCL-1 specific BH3-mimetic drug, was also shown to be effective for the treatment of MM in mouse models, and its effect can be enhanced by co-treatment with the BCL-2 inhibitor venetoclax or the proteasome inhibitor bortezomib [173]. Here, MCL1 is linked to Miyoshi myopathy.